Clinical Trial Update: Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC [Phase 2]

View source ↗

Summary

Clinical trial update for a Phase 2 neoadjuvant hepatic arterial infusion chemotherapy with PD-1 inhibitor and adjuvant PD-1 in high-risk recurrent hepatocellul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• HAIC (hepatic arterial infusion chemotherapy) (hepatic arterial infusion chemotherapy)
• PD-1 inhibitor

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellular Carcinoma, Beyond Milan Criteria | Phase 2 | Status: RECRUITING